{"product_id":"tagrisso","title":"Tagrisso","description":"\u003ch3 data-start=\"268\" data-end=\"291\"\u003eWhat is Tagrisso?\u003c\/h3\u003e\r\n\u003cp data-start=\"292\" data-end=\"700\"\u003e\u003cstrong data-start=\"292\" data-end=\"304\"\u003eTagrisso\u003c\/strong\u003e is an oral targeted therapy used for the treatment of non‑small cell lung cancer (NSCLC) in patients with epidermal growth factor receptor (EGFR) mutations. It is the brand name for the active ingredient \u003cstrong data-start=\"509\" data-end=\"524\"\u003eosimertinib\u003c\/strong\u003e, a third‑generation EGFR tyrosine kinase inhibitor (TKI) that has demonstrated superior efficacy and improved survival outcomes compared to earlier generation EGFR inhibitors.\u003c\/p\u003e\r\n\u003cp data-start=\"702\" data-end=\"796\"\u003e\u003cem data-start=\"702\" data-end=\"796\"\u003eReference: U.S. FDA Tagrisso Prescribing Information; Soria et al., NEJM, 2018 (NCT02296125)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"798\" data-end=\"801\"\u003e\r\n\u003ch3 data-start=\"803\" data-end=\"855\"\u003eWhat are the other popular names for Tagrisso?\u003c\/h3\u003e\r\n\u003cp data-start=\"856\" data-end=\"1086\"\u003eTagrisso is primarily marketed under its brand name \u003cstrong data-start=\"908\" data-end=\"920\"\u003eTagrisso\u003c\/strong\u003e. It is also referred to by its generic name, \u003cstrong data-start=\"966\" data-end=\"981\"\u003eosimertinib\u003c\/strong\u003e. In clinical literature, you may encounter both terms, but Tagrisso remains the widely recognized brand.\u003c\/p\u003e\r\n\u003cp data-start=\"1088\" data-end=\"1122\"\u003e\u003cem data-start=\"1088\" data-end=\"1122\"\u003eReference: MedlinePlus; U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1124\" data-end=\"1127\"\u003e\r\n\u003ch3 data-start=\"1129\" data-end=\"1179\"\u003eWhat is the drug classification of Tagrisso?\u003c\/h3\u003e\r\n\u003cp data-start=\"1180\" data-end=\"1412\"\u003eTagrisso is classified as an \u003cstrong data-start=\"1209\" data-end=\"1249\"\u003eEGFR tyrosine kinase inhibitor (TKI)\u003c\/strong\u003e, specifically a third‑generation TKI. It belongs to the broader category of molecular targeted therapies used in oncology for the treatment of EGFR‑mutated NSCLC.\u003c\/p\u003e\r\n\u003cp data-start=\"1414\" data-end=\"1488\"\u003e\u003cem data-start=\"1414\" data-end=\"1488\"\u003eReference: World Health Organization (WHO) Oncology Guidelines; U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1490\" data-end=\"1493\"\u003e\r\n\u003ch3 data-start=\"1495\" data-end=\"1540\"\u003eWhat is the mode of action of Tagrisso?\u003c\/h3\u003e\r\n\u003cp data-start=\"1541\" data-end=\"1869\"\u003eTagrisso works by irreversibly binding to the mutant forms of the EGFR—including the T790M resistance mutation—thereby blocking the intracellular signaling pathways (e.g., MAPK and PI3K\/AKT) that promote cancer cell proliferation and survival. This results in reduced tumor growth and the induction of apoptosis in cancer cells.\u003c\/p\u003e\r\n\u003cp data-start=\"1871\" data-end=\"1946\"\u003e\u003cem data-start=\"1871\" data-end=\"1946\"\u003eReference: PubMed (Lynch et al., 2004; Soria et al., 2018 NEJM); U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1948\" data-end=\"1951\"\u003e\r\n\u003ch3 data-start=\"1953\" data-end=\"1997\"\u003eWhat are the primary uses of Tagrisso?\u003c\/h3\u003e\r\n\u003cp data-start=\"1998\" data-end=\"2037\"\u003eTagrisso is used in the treatment of:\u003c\/p\u003e\r\n\u003cul data-start=\"2038\" data-end=\"2315\"\u003e\r\n\u003cli data-start=\"2038\" data-end=\"2194\"\u003e\n\u003cstrong data-start=\"2040\" data-end=\"2059\"\u003eAdvanced NSCLC:\u003c\/strong\u003e Particularly in patients with EGFR‑mutated NSCLC, including those with T790M mutation who have progressed on prior EGFR‑TKI therapy.\u003c\/li\u003e\r\n\u003cli data-start=\"2195\" data-end=\"2315\"\u003e\n\u003cstrong data-start=\"2197\" data-end=\"2222\"\u003eFirst‑line Treatment:\u003c\/strong\u003e It is also approved as a first‑line therapy for patients with EGFR‑mutated metastatic NSCLC.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2317\" data-end=\"2385\"\u003e\u003cem data-start=\"2317\" data-end=\"2385\"\u003eReference: U.S. FDA; ClinicalTrials.gov (NCT02296125, NCT02511106)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2387\" data-end=\"2390\"\u003e\r\n\u003ch3 data-start=\"2392\" data-end=\"2461\"\u003eWhat is the recommended dosage and administration for Tagrisso?\u003c\/h3\u003e\r\n\u003cul data-start=\"2462\" data-end=\"2736\"\u003e\r\n\u003cli data-start=\"2462\" data-end=\"2545\"\u003e\n\u003cstrong data-start=\"2464\" data-end=\"2475\"\u003eDosage:\u003c\/strong\u003e The standard dose of Tagrisso is \u003cstrong data-start=\"2509\" data-end=\"2529\"\u003e80 mg once daily\u003c\/strong\u003e taken orally.\u003c\/li\u003e\r\n\u003cli data-start=\"2546\" data-end=\"2736\"\u003e\n\u003cstrong data-start=\"2548\" data-end=\"2567\"\u003eAdministration:\u003c\/strong\u003e\r\n\u003cul data-start=\"2572\" data-end=\"2736\"\u003e\r\n\u003cli data-start=\"2572\" data-end=\"2649\"\u003eTagrisso should be taken at the same time each day, with or without food.\u003c\/li\u003e\r\n\u003cli data-start=\"2652\" data-end=\"2733\"\u003eConsistency in dosing helps maintain steady plasma levels for optimal efficacy.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2737\" data-end=\"2811\"\u003e\u003cem data-start=\"2737\" data-end=\"2811\"\u003eReference: U.S. FDA Tagrisso Prescribing Information; ClinicalTrials.gov\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2813\" data-end=\"2816\"\u003e\r\n\u003ch3 data-start=\"2818\" data-end=\"2879\"\u003eWhat prescribing information is important for Tagrisso?\u003c\/h3\u003e\r\n\u003cul data-start=\"2880\" data-end=\"3494\"\u003e\r\n\u003cli data-start=\"2880\" data-end=\"3023\"\u003e\n\u003cstrong data-start=\"2882\" data-end=\"2898\"\u003eIndications:\u003c\/strong\u003e\r\n\u003cul data-start=\"2903\" data-end=\"3023\"\u003e\r\n\u003cli data-start=\"2903\" data-end=\"3023\"\u003eTagrisso is indicated for the treatment of patients with metastatic NSCLC whose tumors have specific EGFR mutations.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3024\" data-end=\"3160\"\u003e\n\u003cstrong data-start=\"3026\" data-end=\"3048\"\u003eContraindications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3053\" data-end=\"3160\"\u003e\r\n\u003cli data-start=\"3053\" data-end=\"3160\"\u003eIt is contraindicated in patients with a known hypersensitivity to osimertinib or any of its ingredients.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3161\" data-end=\"3319\"\u003e\n\u003cstrong data-start=\"3163\" data-end=\"3178\"\u003eMonitoring:\u003c\/strong\u003e\r\n\u003cul data-start=\"3183\" data-end=\"3319\"\u003e\r\n\u003cli data-start=\"3183\" data-end=\"3319\"\u003eRegular monitoring for adverse effects, including pulmonary symptoms, liver function, and QT interval changes via ECG, is recommended.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3320\" data-end=\"3494\"\u003e\n\u003cstrong data-start=\"3322\" data-end=\"3349\"\u003eSpecial Considerations:\u003c\/strong\u003e\r\n\u003cul data-start=\"3354\" data-end=\"3494\"\u003e\r\n\u003cli data-start=\"3354\" data-end=\"3421\"\u003eEGFR mutation testing is essential prior to initiating therapy.\u003c\/li\u003e\r\n\u003cli data-start=\"3424\" data-end=\"3494\"\u003eUse caution in patients with a history of interstitial lung disease.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3496\" data-end=\"3554\"\u003e\u003cem data-start=\"3496\" data-end=\"3554\"\u003eReference: U.S. FDA; NCCN Guidelines; ClinicalTrials.gov\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"3556\" data-end=\"3559\"\u003e\r\n\u003ch3 data-start=\"3561\" data-end=\"3658\"\u003eWhat safety information, side effects, warnings, and cautions are associated with Tagrisso?\u003c\/h3\u003e\r\n\u003cul data-start=\"3659\" data-end=\"4616\"\u003e\r\n\u003cli data-start=\"3659\" data-end=\"3825\"\u003e\n\u003cstrong data-start=\"3661\" data-end=\"3685\"\u003eCommon Side Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"3690\" data-end=\"3825\"\u003e\r\n\u003cli data-start=\"3690\" data-end=\"3782\"\u003eDiarrhea, rash, dry skin, nail toxicity, and paronychia (inflammation around the nails).\u003c\/li\u003e\r\n\u003cli data-start=\"3785\" data-end=\"3825\"\u003eMild pulmonary symptoms such as cough.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3826\" data-end=\"4006\"\u003e\n\u003cstrong data-start=\"3828\" data-end=\"3853\"\u003eSerious Side Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"3858\" data-end=\"4006\"\u003e\r\n\u003cli data-start=\"3858\" data-end=\"3937\"\u003eInterstitial lung disease (ILD)\/pneumonitis, which can be life‑threatening.\u003c\/li\u003e\r\n\u003cli data-start=\"3940\" data-end=\"4006\"\u003eQT interval prolongation, which may lead to cardiac arrhythmias.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4007\" data-end=\"4412\"\u003e\n\u003cstrong data-start=\"4009\" data-end=\"4033\"\u003eWarnings \u0026amp; Cautions:\u003c\/strong\u003e\r\n\u003cul data-start=\"4038\" data-end=\"4412\"\u003e\r\n\u003cli data-start=\"4038\" data-end=\"4135\"\u003e\n\u003cstrong data-start=\"4040\" data-end=\"4063\"\u003ePulmonary Toxicity:\u003c\/strong\u003e Patients must be monitored for new or worsening respiratory symptoms.\u003c\/li\u003e\r\n\u003cli data-start=\"4138\" data-end=\"4231\"\u003e\n\u003cstrong data-start=\"4140\" data-end=\"4163\"\u003eCardiac Monitoring:\u003c\/strong\u003e ECG monitoring is recommended due to the risk of QT prolongation.\u003c\/li\u003e\r\n\u003cli data-start=\"4234\" data-end=\"4305\"\u003e\n\u003cstrong data-start=\"4236\" data-end=\"4255\"\u003eHepatotoxicity:\u003c\/strong\u003e Liver enzymes should be monitored periodically.\u003c\/li\u003e\r\n\u003cli data-start=\"4308\" data-end=\"4412\"\u003e\n\u003cstrong data-start=\"4310\" data-end=\"4337\"\u003eDermatologic Reactions:\u003c\/strong\u003e Severe skin reactions, although rare, require immediate medical attention.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4413\" data-end=\"4616\"\u003e\n\u003cstrong data-start=\"4415\" data-end=\"4443\"\u003ePregnancy and Lactation:\u003c\/strong\u003e\r\n\u003cul data-start=\"4448\" data-end=\"4616\"\u003e\r\n\u003cli data-start=\"4448\" data-end=\"4616\"\u003eTagrisso is contraindicated in pregnant women due to potential teratogenic effects. Women of childbearing potential must use effective contraception during treatment.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4618\" data-end=\"4686\"\u003e\u003cem data-start=\"4618\" data-end=\"4686\"\u003eReference: U.S. FDA Tagrisso Prescribing Information; NEJM; PubMed\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"4688\" data-end=\"4691\"\u003e\r\n\u003ch3 data-start=\"4693\" data-end=\"4757\"\u003eWhat drug interactions should be considered with Tagrisso?\u003c\/h3\u003e\r\n\u003cul data-start=\"4758\" data-end=\"5253\"\u003e\r\n\u003cli data-start=\"4758\" data-end=\"4942\"\u003e\n\u003cstrong data-start=\"4760\" data-end=\"4791\"\u003eCYP3A4 Inhibitors\/Inducers:\u003c\/strong\u003e\r\n\u003cul data-start=\"4796\" data-end=\"4942\"\u003e\r\n\u003cli data-start=\"4796\" data-end=\"4942\"\u003eStrong CYP3A4 inhibitors (e.g., ketoconazole) may increase osimertinib levels, while inducers (e.g., rifampin) may decrease its effectiveness.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4943\" data-end=\"5078\"\u003e\n\u003cstrong data-start=\"4945\" data-end=\"4975\"\u003eOther QT-Prolonging Drugs:\u003c\/strong\u003e\r\n\u003cul data-start=\"4980\" data-end=\"5078\"\u003e\r\n\u003cli data-start=\"4980\" data-end=\"5078\"\u003eConcurrent use with drugs that prolong the QT interval should be avoided or monitored carefully.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5079\" data-end=\"5253\"\u003e\n\u003cstrong data-start=\"5081\" data-end=\"5094\"\u003eAntacids:\u003c\/strong\u003e\r\n\u003cul data-start=\"5099\" data-end=\"5253\"\u003e\r\n\u003cli data-start=\"5099\" data-end=\"5253\"\u003eWhile not a major interaction, antacids may slightly affect the absorption of Tagrisso; it is advisable to separate administration by a couple of hours.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5255\" data-end=\"5317\"\u003e\u003cem data-start=\"5255\" data-end=\"5317\"\u003eReference: U.S. FDA; Clinical Pharmacology Reviews on PubMed\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5319\" data-end=\"5322\"\u003e\r\n\u003ch3 data-start=\"5324\" data-end=\"5361\"\u003eFrequently Asked Questions (FAQs)\u003c\/h3\u003e\r\n\u003cp data-start=\"5363\" data-end=\"5579\"\u003e\u003cstrong data-start=\"5363\" data-end=\"5421\"\u003eQ: How soon can I expect to see results with Tagrisso?\u003c\/strong\u003e\u003cbr data-start=\"5421\" data-end=\"5424\"\u003eA: Many patients begin to experience symptom improvement within a few weeks, although full clinical benefits may take several months of continuous therapy.\u003c\/p\u003e\r\n\u003cp data-start=\"5581\" data-end=\"5763\"\u003e\u003cstrong data-start=\"5581\" data-end=\"5648\"\u003eQ: Is EGFR mutation testing necessary before starting Tagrisso?\u003c\/strong\u003e\u003cbr data-start=\"5648\" data-end=\"5651\"\u003eA: Yes, EGFR mutation testing is essential to identify patients who are likely to benefit from Tagrisso therapy.\u003c\/p\u003e\r\n\u003cp data-start=\"5765\" data-end=\"5948\"\u003e\u003cstrong data-start=\"5765\" data-end=\"5804\"\u003eQ: Can Tagrisso be taken with food?\u003c\/strong\u003e\u003cbr data-start=\"5804\" data-end=\"5807\"\u003eA: Yes, Tagrisso can be taken with or without food; however, it should be taken at the same time each day to ensure consistent plasma levels.\u003c\/p\u003e\r\n\u003cp data-start=\"5950\" data-end=\"6177\"\u003e\u003cstrong data-start=\"5950\" data-end=\"6029\"\u003eQ: What should I do if I experience respiratory symptoms while on Tagrisso?\u003c\/strong\u003e\u003cbr data-start=\"6029\" data-end=\"6032\"\u003eA: Report any new or worsening respiratory symptoms immediately, as they could be signs of interstitial lung disease, a serious adverse reaction.\u003c\/p\u003e\r\n\u003cp data-start=\"6179\" data-end=\"6389\"\u003e\u003cstrong data-start=\"6179\" data-end=\"6223\"\u003eQ: Can I take Tagrisso if I am pregnant?\u003c\/strong\u003e\u003cbr data-start=\"6223\" data-end=\"6226\"\u003eA: Tagrisso is contraindicated during pregnancy due to the risk of fetal harm. Women of childbearing potential should use effective contraception during treatment.\u003c\/p\u003e\r\n\u003cp data-start=\"6391\" data-end=\"6437\"\u003e\u003cem data-start=\"6391\" data-end=\"6437\"\u003eReference: U.S. FDA; NCCN Guidelines; PubMed\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"6439\" data-end=\"6442\"\u003e\r\n\u003ch3 data-start=\"6444\" data-end=\"6536\"\u003eWhere can I find additional clinical evidence and detailed information about Tagrisso?\u003c\/h3\u003e\r\n\u003cp data-start=\"6537\" data-end=\"6642\"\u003eFor further information on clinical studies, dosing guidelines, and safety monitoring, please refer to:\u003c\/p\u003e\r\n\u003cul data-start=\"6643\" data-end=\"7071\"\u003e\r\n\u003cli data-start=\"6643\" data-end=\"6731\"\u003e\n\u003cstrong data-start=\"6645\" data-end=\"6697\"\u003eU.S. Food and Drug Administration (FDA) Website:\u003c\/strong\u003e \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"6698\" data-end=\"6729\"\u003eFDA.gov\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"6732\" data-end=\"6820\"\u003e\n\u003cstrong data-start=\"6734\" data-end=\"6757\"\u003eClinicalTrials.gov:\u003c\/strong\u003e Search for Tagrisso studies (e.g., NCT02296125, NCT02511106)\u003c\/li\u003e\r\n\u003cli data-start=\"6821\" data-end=\"6911\"\u003e\n\u003cstrong data-start=\"6823\" data-end=\"6866\"\u003eNew England Journal of Medicine (NEJM):\u003c\/strong\u003e Publications on Tagrisso efficacy in NSCLC\u003c\/li\u003e\r\n\u003cli data-start=\"6912\" data-end=\"6978\"\u003e\n\u003cstrong data-start=\"6914\" data-end=\"6925\"\u003ePubMed:\u003c\/strong\u003e For peer‑reviewed research articles on osimertinib\u003c\/li\u003e\r\n\u003cli data-start=\"6979\" data-end=\"7071\"\u003e\n\u003cstrong data-start=\"6981\" data-end=\"7041\"\u003eNational Comprehensive Cancer Network (NCCN) Guidelines:\u003c\/strong\u003e For NSCLC treatment protocols\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"7073\" data-end=\"7134\"\u003e\u003cem data-start=\"7073\" data-end=\"7134\"\u003eReference: U.S. FDA; ClinicalTrials.gov; NEJM; PubMed; NCCN\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"7136\" data-end=\"7139\"\u003e\r\n\u003ch3 data-start=\"7141\" data-end=\"7161\"\u003eFinal Thoughts\u003c\/h3\u003e\r\n\u003cp data-start=\"7162\" data-end=\"7893\"\u003e\u003cstrong data-start=\"7162\" data-end=\"7188\"\u003eTagrisso (osimertinib)\u003c\/strong\u003e is a critical targeted therapy for patients with EGFR‑mutated non‑small cell lung cancer. Its ability to irreversibly inhibit EGFR tyrosine kinase activity—including resistant T790M mutations—translates into improved progression‑free survival and overall outcomes in patients with advanced NSCLC. However, careful patient selection through molecular testing, regular monitoring for adverse events (especially pulmonary and cardiac), and management of potential drug interactions are essential to ensure safe and effective use. Always consult your healthcare provider to determine whether Tagrisso is appropriate for your specific condition and to manage its use as part of a comprehensive treatment plan.\u003c\/p\u003e\r\n\u003cp data-start=\"7895\" data-end=\"8113\"\u003e\u003cem data-start=\"7895\" data-end=\"8113\"\u003eDisclaimer: This guide is provided for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.\u003c\/em\u003e\u003c\/p\u003e","brand":"EZ Chemist","offers":[{"title":"40mg","offer_id":51735725900059,"sku":"Tagrisso (Osimertinib) 40mg x 10 Tablets-40mg","price":2490.0,"currency_code":"USD","in_stock":true},{"title":"80mg","offer_id":51735725932827,"sku":"Tagrisso (Osimertinib) 40mg x 10 Tablets-80mg","price":2730.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0992\/3303\/8619\/files\/untitled_design_79.png?v=1770407757","url":"https:\/\/ezchemist.com\/products\/tagrisso","provider":"EZ Chemist","version":"1.0","type":"link"}